ArticleBMC cancer2025
Clinical relevance of perioperative changes in circulating tumor cells in resectable colorectal cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Preventing surgery-induced natural killer cell suppression and metastases by inhibiting PI3K-gamma signaling in myeloid-derived suppressor cells.Journal for immunotherapy of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChanges in circulating tumor cells (CTCs) before and after surgery and their association with lymph node metastasis and prognosis in resectable colorectal cancer (CRC) remain poorly understood.
methodsIn this prospective study, 81 patients with resectable CRC treated at Jiangyin People's Hospital from January 2023 to December 2024 were enrolled, along with 20 controls with adenoma. Preoperative and Postoperative peripheral blood CTCs were quantified using microfluidic chip technology.
resultsThe median CTC count significantly declined from 16 per 5 ml to 4 after surgery (P < 0.001). Preoperatively, 76.6% were CTC-positive. Postoperatively, the CTC-positive rate decreased to 56.8% (P < 0.001). Of the 81 patients, 36 had lymph node metastasis (LNM), and 45 did not. Univariate analysis identified T3-4 stage, nerve invasion, vascular invasion, and preoperative CTC positivity as significant predictors of LNM (P < 0.05). Multivariate logistic regression confirmed vascular invasion (odds ratio [OR], 20.528; 95% CI, 4.296-98.086; P < 0.001) and preoperative CTC positivity (OR, 8.017; 95% CI, 1.138-56.482; P = 0.037) as independent risk factors for LNM. Prognostic analysis revealed that postoperative CTC-negative status was significantly associated with improved disease-free survival (DFS) (Log-rank P = 0.047).
conclusionsPreoperative CTC positivity was significantly associated with an increased risk of lymph node metastasis, supporting its potential role in assessing tumor aggressiveness. In addition, postoperative CTC positivity showed an exploratory association with shorter disease-free survival, suggesting a possible prognostic value that warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.